

Initial coverage Modus: Promising Phase I candidate in huge market

Carlsquare Equity Research initiates coverage of the biotechnology company Modus Therapeutics Holding.

The Company is developing the drug candidate sevuparin for the serious condition Sepsis/septic shock. The candidate has shown robust safety data in previous studies. Although sevuparin is theoretically ready for a phase II study, Modus is valued as an early-stage preclinical company. We see significant potential for sevuparin and Modus for the next 12 months.

[Read the full report here.](#)

About Carlsquare

Carlsquare is a Pan-European research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 80+ employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team have an extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Berlin, Copenhagen, Hamburg, London, Munich and Stockholm. [Read more](#)

Contact

MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

Contacts

MARKUS AUGUSTSSON

Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

JONATAN ANDERSSON

Equity Analyst
jonatan.andersson@carlsquare.com
+46 (0)70 508 00 51

Attachments

[Initial coverage Modus: Promising Phase I candidate in huge market](#)

